Market research

FLNA Filana Therapeutics, Inc.

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 37M
P/E ratio: Not available
Analyst target: 6.5
Dividend yield: Not available
Beta: -0.7

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US14817C1071
Market cap: 37M
P/E ratio: Not available
Analyst target: 6.5
Dividend yield: Not available
Beta: -0.7

About

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about FLNA.

FLNA Filana Therapeutics, Inc.

Price & volume

Company facts

About Filana Therapeutics, Inc.

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet